Abbott Laboratories (ABT) Fair Value & Analysis

Healthcare · US · Market cap $175B · ISIN US0028241000

What is Abbott Laboratories really worth?

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case ($94.43). The favourable scenario is already priced in.
• Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range ($51.13 to $94.43) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 31, 2026.

How to read this chart

60‑month range $81.98 – $135.81 · fair‑value band $51.13 – $94.43 · the $108.79 price screens above the $74.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 31, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Abbott Laboratories (ABT) currently trades at $108.79, while our model-based Fair Value estimate is $74.79, implying the stock looks roughly 45.5% overvalued today. The Quality Score stands at 67/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of $70.97 per share, and 0 of the 26 models we run sit above the $108.79 price. Bear case: the Asset-Based group reads lowest at $20.05, and 26 of the 26 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, Abbott Laboratories generated revenue of $45.1B at a net margin of 13.9%. Revenue grew 7.8% year over year. It earns a return on equity of 12.3%. Net debt stands at $6.5B. Fundamentals as of Aug 31, 2026

Our scenario range runs from $51.13 (bear case) to $94.43 (bull case); at $108.79, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 20% below its 52-week high and 33% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −31%, ABT screens richer than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $0.8053 per share, which is 1.1 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Widest divergence: DCF Models ($70.97) versus Asset-Based ($20.05). Highest evidence: FCF DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

Full company description

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Abbott Laboratories reported revenue of $44.3B in FY2025 versus $43.1B in FY2021, a compound +0.7%/yr. Reported net income was $6.5B in FY2025, compounding −2.0%/yr from FY2021.

ABT screens 45% overvalued. Compare with Stryker Corporation →

Recent news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

• FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking Yahoo Finance · Aug 28, 2026
• Abbott (ABT) Stock Sinks As Market Gains: Here's Why Yahoo Finance · Aug 27, 2026

Peer Group

Medical Devices · 351 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Devices median · lower = cheaper

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 31, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions